Regeneron Reports First Quarter 2018 Financial and Operating Results

Thursday, May 3, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

TABLE 4

REGENERON PHARMACEUTICALS, INC.

COLLABORATION AND OTHER REVENUE (Unaudited)

(In thousands)

Three Months Ended March 31,

2018

2017

Sanofi collaboration revenue:

Reimbursement of Regeneron research and development expenses

$

134,218

$

213,924

Reimbursement of Regeneron commercialization-related expenses

86,634

73,559

Regeneron's share of losses in connection with commercialization of antibodies

(74,874)

(108,402)

Other

43,512

31,286

  Total Sanofi collaboration revenue

189,490

210,367

Bayer collaboration revenue:

Regeneron's net profit in connection with commercialization of EYLEA outside the    United States

232,068

174,876

Reimbursement of Regeneron development expenses

3,997

6,349

Other

11,863

12,714

  Total Bayer collaboration revenue

247,928

193,939

Total Sanofi and Bayer collaboration revenue

$

437,418

$

404,306

Other revenue:

Reimbursement of Regeneron research and development expenses - Teva

$

39,129

$

22,050

Reimbursement of Regeneron research and development expenses - other

2,695

2,650

Other

44,334

31,740

  Total other revenue

$

86,158

$

56,440

Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store